Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and immune response of an Acne mRNA vaccine in adults aged 18 to 45 years with moderate to severe acne. This Phase III study is the first to test this vaccine in humans and aims to find the best dose to use in future larger trials. Acne is a common inflammatory skin condition that affects millions worldwide, and current treatments have not changed much over the past 30 years. This study is sponsored by Sanofi Pasteur, a Sanofi Company. The trial includes up to three intramuscular injections of the Acne mRNA vaccine at different dose levels. Participants are divided into four groups two groups receive two injections and two groups receive three injections. Each vaccination group has a matching placebo group for comparison. The Core Study includes Sentinel and Main cohorts for both the two- and three-dose regimens. After completing the Core Study, some participants will enter a long-term follow-up period lasting up to 30 months to assess lasting effects of the vaccine. One group will be invited to join a separate long-term extension study. During the study, participants will be closely monitored for side effects shortly after each injection and for several months thereafter. Researchers will measure changes in the number of acne lesions and immune responses through blood tests. Safety assessments include tracking any adverse events and laboratory test results. Visits will include medical evaluations and questionnaires. The total participation time may extend beyond the Core Study to include long-term follow-up for some participants, lasting up to 38 to 40 months after the first injection.
Actively Recruiting
This research aims to assess the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have severe alopecia areata, characterized by 50% or greater scalp hair loss. The study includes a double-blind, randomized, placebo-controlled treatment phase followed by an open-label extension. The goal is to better understand how well deuruxolitinib works and how safe it is for this age group with significant hair loss. Participants will be randomly assigned to receive either deuruxolitinib tablets or matching placebo tablets taken orally twice daily for 24 weeks during the initial treatment period. Following this, all participants will have the opportunity to receive deuruxolitinib for an additional 52 weeks in an open-label extension phase. This design allows comparison of the drug to placebo and longer-term evaluation of the drugs effects. Throughout the study, participants will have regular assessments of their hair loss using the Severity of Alopecia Tool SALT at multiple time points up to week 24 and beyond. Safety will be closely monitored by tracking side effects, vital signs, heart tests, lab results, and physical exams. Additional measurements include patient and clinician impressions of improvement, quality of life, and mental health assessments. The total study duration can extend up to 76 weeks of treatment plus safety follow-up to fully evaluate outcomes and tolerability.
Actively Recruiting
Researchers are studying atopic dermatitis AD in adolescents and adults to better understand the unmet needs across this condition and to observe how systemic treatments work in real-world settings. This observational study aims to explore patients journeys, including factors like age, skin color, flare triggers, past treatment responses, comorbidities, and lesion characteristics. It involves multiple countries and diverse populations to capture a broad picture of treatment impacts over time. The study follows patients who begin or switch any systemic treatment for AD, such as biologics, oral Janus kinase inhibitors, cyclosporine, azathioprine, methotrexate, or mycophenolate mofetil, as prescribed by their doctors based on local guidelines. Researchers do not assign treatments but collect information on treatment choices and changes during standard care. This registry will track treatment sequences, interruptions, dose changes, and reasons for starting or stopping treatments over a five-year period. Participants will be followed for up to five years to monitor their treatment experience and disease progression. Data collection includes assessments of disease severity using tools like the Eczema Area and Severity Index EASI, body surface area affected, and global assessments of AD. Patient-reported outcomes such as itch, skin pain, sleep disturbance, quality of life, work productivity, and treatment satisfaction will also be recorded. Safety will be monitored through reports of adverse events. The study collects demographics, comorbid conditions, healthcare visits, and medication use to provide a comprehensive view of AD management in everyday care.